Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

Open in Screener

LXEO

Lexeo Therapeutics Inc

Feb 13 • 04:00PM ET

6.31

-0.26 -3.96 %

Healthcare • Biotechnology • USA • NASD

Peers: CRSP QURE SRPT NTLA BEAM RARE BLUE EDIT SGMO ADVM

| Held by: VTI XBI IWM VXF IWN VTWO IBB KOMP VFMO IWC

Index	RUT	P/E	-	EPS (ttm)	-2.70	Insider Own	17.40%	Shs Outstand	72.99M	Perf Week	-11.87%
Market Cap	460.55M	Forward P/E	-	EPS next Y	-1.52	Insider Trans	-0.29%	Shs Float	60.28M	Perf Month	-18.26%
Enterprise Value	346.25M	PEG	-	EPS next Q	-0.31	Inst Own	82.95%	Short Float	19.87%	Perf Quarter	-31.49%
Income	-104.97M	P/S	-	EPS this Y	37.04%	Inst Trans	14.92%	Short Ratio	9.69	Perf Half Y	31.73%
Sales	0.00M	P/B	2.87	EPS next Y	21.84%	ROA	-66.08%	Short Interest	11.98M	Perf YTD	-36.46%
Book/sh	2.20	P/C	3.75	EPS next 5Y	24.04%	ROE	-80.69%	52W High	10.99 -42.58%	Perf Year	49.53%
Cash/sh	1.68	P/FCF	-	EPS past 3/5Y	-17.65% -99.98%	ROIC	-82.93%	52W Low	1.45 335.17%	Perf 3Y	-
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	6.79% 6.26%	Perf 5Y	-
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	4.97%	Oper. Margin	-	ATR (14)	0.56	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	7.40	Sales Y/Y TTM	-	Profit Margin	-	RSI (14)	30.63	Recom	1.09
Dividend Gr. 3/5Y	- -	Current Ratio	7.40	EPS Q/Q	62.71%	SMA20	-12.92%	Beta	1.89	Target Price	19.64
Payout	-	Debt/Eq	0.07	Sales Q/Q	-	SMA50	-26.69%	Rel Volume	0.33	Prev Close	6.57
Employees	72	LT Debt/Eq	0.05	Earnings	Nov 05 BMO	SMA200	-1.12%	Avg Volume	1.24M	Price	6.31
IPO	Nov 03, 2023	Option/Short	Yes / Yes	EPS/Sales Surpr.	36.54% -	Trades		Volume	408,060	Change	-3.96%

Date	Action	Analyst	Rating Change	Price Target Change
Dec-18-25	Initiated	Raymond James	Strong Buy	$25
Nov-20-25	Initiated	Cantor Fitzgerald	Overweight	$19
Oct-15-25	Initiated	Guggenheim	Buy	$30
Jul-31-25	Initiated	Oppenheimer	Outperform	$20
Jun-13-24	Initiated	Robert W. Baird	Outperform	$28
Jun-06-24	Initiated	H.C. Wainwright	Buy	$22
Nov-28-23	Initiated	Stifel	Buy	$20
Nov-28-23	Initiated	RBC Capital Mkts	Outperform	$22
Nov-28-23	Initiated	Leerink Partners	Outperform	$19
Nov-28-23	Initiated	JP Morgan	Overweight	$20
Nov-28-23	Initiated	Chardan Capital Markets	Buy	$23

Show Previous Ratings

Feb-05-26 07:30AM	Lexeo Therapeutics to Participate in Upcoming Investor Conferences in February (GlobeNewswire) -5.23%
Feb-02-26 09:54AM	H.C. Wainwright Says Market Remains Unconvinced on Lexeo Therapeutics, Inc. (LXEO)'s PKP2 Program (Insider Monkey)
Jan-27-26 07:30AM	Lexeo Therapeutics Announces Key Leadership Appointments Strengthening Cardiovascular Expertise Alongside Updates to Strategic Partnership for Novel Cardiac RNA Therapeutics (GlobeNewswire)
Jan-12-26 07:00AM	Lexeo Therapeutics Announces Positive Interim Phase I/II Data for LX2020 for the Treatment of PKP2-Associated Arrhythmogenic Cardiomyopathy (GlobeNewswire) -22.96%
Jan-09-26 06:28AM	Insmeds ginormous lung drug sales; J&Js US pricing deal (BioPharma Dive) +11.30%
07:00AM	Loading…
Jan-08-26 07:00AM	Lexeo Therapeutics Announces Research Collaboration to Explore Targeted Cardiac Delivery of AAV Gene Therapy (GlobeNewswire) -5.49%
Dec-27-25 07:28AM	Wall Street Rallies Behind Lexeo Therapeutics (LXEO)'s Gene Therapy Pipeline (Insider Monkey)
Dec-25-25 07:00PM	Raymond James Sees an Attractive Setup in These 2 Strong Buy Stocks (TipRanks)
Dec-22-25 07:30AM	Lexeo Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-04-25 08:00AM	Lexeo Therapeutics to Host Virtual Key Opinion Leader Event at the 22nd Global Cardiovascular Clinical Trialists (CVCT) Forum (GlobeNewswire)
Nov-11-25 09:55AM	Wall Street Analysts Predict a 124.3% Upside in Lexeo Therapeutics, Inc. (LXEO): Here's What You Should Know (Zacks) +7.04%
Nov-05-25 07:36AM	Lexeo Therapeutics Reports Third Quarter 2025 Financial Results and Operational Highlights (GlobeNewswire)
Nov-03-25 05:32AM	Is Lexeo Therapeutics (LXEO) One of Billionaire Daniel Sundheim's Stock Picks with Huge Upside Potential (Insider Monkey) -9.69%
Oct-26-25 06:05AM	Lexeo Therapeutics (LXEO) Gets a PT Cut to $13 by H.C. Wainwright Due to Equity Raise (Insider Monkey)
Oct-23-25 09:55AM	Wall Street Analysts See a 108.23% Upside in Lexeo Therapeutics, Inc. (LXEO): Can the Stock Really Move This High? (Zacks)
09:20AM	Loading…
Oct-21-25 09:20AM	Beyond Traditional Drugs: Novel Platforms Targeting Hard-to-Treat Conditions (PR Newswire)
Oct-20-25 04:05PM	Lexeo Therapeutics Announces Closing of Public Offering and Concurrent Private Placement and Exercise in Full of the Underwriters' Option to Purchase Additional Shares in the Public Offering (GlobeNewswire)
Oct-17-25 09:27AM	Lexeo Therapeutics Announces FDA Support for Accelerated Approval Pathway, Positive Interim Data for Gene Therapy LX2006 (Insider Monkey) +9.24%
Oct-16-25 11:29PM	Lexeo Therapeutics Announces Pricing of Public Offering and Concurrent Private Placement (GlobeNewswire)
04:32PM	Lexeo Therapeutics Announces Proposed Offering of Common Stock and Pre-Funded Warrants (GlobeNewswire)
Oct-08-25 10:58AM	Breakthrough Discoveries Unlock $643B Cancer Treatment Market By 2034 (PR Newswire)
Oct-07-25 06:00AM	Lexeo Therapeutics Announces Progress in FDA Discussions for Accelerated Approval Pathway and Positive Interim Clinical Data for LX2006 in Friedreich Ataxia Cardiomyopathy (GlobeNewswire) +28.90%
Aug-14-25 07:30AM	Lexeo Therapeutics Reports Second Quarter 2025 Financial Results and Operational Highlights (GlobeNewswire)
Jul-31-25 09:46AM	Meta, Microsoft upgraded: Wall Street's top analyst calls (The Fly)
Jul-29-25 10:23AM	Stifel Maintains Buy Rating on Lexeo Therapeutics (LXEO) (Insider Monkey)
Jul-07-25 07:00AM	Lexeo Therapeutics Announces FDA Breakthrough Therapy Designation for LX2006 in Friedreich Ataxia (GlobeNewswire)
Jun-24-25 07:30AM	Lexeo Therapeutics, Perceptive Xontogeny Venture Funds and venBio Partners Announce Partnership to Advance Novel Cardiac RNA Therapeutics (GlobeNewswire) +6.31%
May-27-25 07:31AM	Lexeo Therapeutics Announces $80 Million Equity Financing to Further Advance Development of Transformative Genetic Medicines for Cardiovascular Diseases (GlobeNewswire)
May-12-25 07:00AM	Lexeo Therapeutics Reports First Quarter 2025 Financial Results and Operational Highlights (GlobeNewswire)
May-05-25 02:19PM	Lexeo: Alignment Gained With FDA Brings Further LX2006 Program Advancement (Seeking Alpha)
09:16AM	Loading…
May-01-25 09:16AM	Lexeo Therapeutics to Present New CMC Data at the 28th American Society of Gene & Cell Therapy (ASGCT) Annual Meeting (GlobeNewswire) +19.85%
Apr-07-25 06:00AM	Lexeo Therapeutics Announces Positive Interim Phase 1/2 Data for LX2006 in Friedreich Ataxia Cardiomyopathy Supporting Advancement to Registrational Study (GlobeNewswire) -23.34%
Mar-25-25 09:10AM	Pharma Frenzy: Volatility Ignites Biotech Sector (MarketBeat) +8.56%
08:44AM	Why Lexeo Therapeutics (LXEO) Skyrocketed on Monday? (Insider Monkey)
Mar-24-25 07:00AM	Lexeo Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Operational Highlights (GlobeNewswire) +50.92%
Jan-07-25 07:30AM	Lexeo Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-19-24 07:00AM	Lexeo Therapeutics Appoints Kyle Rasbach as Chief Financial Officer (GlobeNewswire) -5.03%
Dec-02-24 07:00AM	Satellos to Participate in Duchenne KOL Investor Webinar on December 4, 2024 (Business Wire)
Nov-13-24 07:30AM	Lexeo Therapeutics Provides Update on Cardiac Portfolio and Reports Third Quarter 2024 Financial Results (GlobeNewswire)
Oct-30-24 06:14AM	Lexeo Therapeutics Announces Positive Interim Data for LX1001, First-Ever Gene Therapy to Impact the Underlying Genetic Cause of APOE4-Associated Alzheimer's Disease, at the Clinical Trials on Alzheimer's Disease (CTAD) Conference (GlobeNewswire) -17.00%
Oct-22-24 07:30AM	Lexeo Therapeutics to Present New Interim Data from Phase 1/2 Trial of LX1001 at the Clinical Trials on Alzheimer's Disease (CTAD) 2024 Conference (GlobeNewswire)
Sep-05-24 07:30AM	Lexeo Therapeutics to Participate in Upcoming Investor Conferences (GlobeNewswire)
Aug-12-24 07:00AM	Lexeo Therapeutics Reports Second Quarter 2024 Financial Results and Operational Highlights (GlobeNewswire)
Jul-16-24 11:03AM	Lexeo (LXEO) Down Despite Upbeat Rare Disease Gene Therapy Data (Zacks)
Jul-15-24 04:17PM	Why Lexeo Therapeutics Collapsed 26%, Sacrificing A Breakout In Bearish Fashion (Investor's Business Daily) -26.08%
10:11AM	Why Top 4% Biotech Stock Lexeo Therapeutics Just Gave Up A Breakout (Investor's Business Daily)
06:36AM	Lexeo gene therapy shows signs of heart benefit in small study (BioPharma Dive)
06:00AM	Lexeo Therapeutics Announces Positive Interim Phase 1/2 Clinical Data of LX2006 for the Treatment of Friedreich Ataxia Cardiomyopathy (GlobeNewswire)
Jul-11-24 08:00AM	Lexeo Therapeutics Announces Investor Webcast to Report Interim Phase 1/2 Clinical Data of LX2006 for the Treatment of Friedreich Ataxia Cardiomyopathy on Monday, July 15, 2024 (GlobeNewswire) +6.08%
Jul-08-24 07:00AM	Lexeo Therapeutics Appoints Tim Van Hauwermeiren to its Board of Directors (GlobeNewswire) +5.55%
May-14-24 12:00PM	What Makes Lexeo Therapeutics, Inc. (LXEO) a New Buy Stock (Zacks)
09:55AM	Wall Street Analysts Think Lexeo Therapeutics, Inc. (LXEO) Could Surge 57.82%: Read This Before Placing a Bet (Zacks)
May-09-24 07:00AM	Lexeo Therapeutics Reports First Quarter 2024 Financial Results and Operational Highlights (GlobeNewswire) +5.69%
May-07-24 07:30AM	Lexeo Therapeutics to Participate in Upcoming Investor Conferences (GlobeNewswire)
Apr-22-24 07:30AM	Lexeo Therapeutics Announces License Agreement to Accelerate Development of LX2006 for the Treatment of Friedreich Ataxia Cardiomyopathy (GlobeNewswire) +5.06%
Apr-16-24 07:30AM	Lexeo Therapeutics Granted FDA Fast Track Designation for LX2006, an AAV-Based Gene Therapy Candidate for the Treatment of Friedreich's Ataxia Cardiomyopathy (GlobeNewswire)
Mar-13-24 04:22PM	Lexeo Therapeutics Announces Closing of Oversubscribed $95.0 Million Equity Financing (GlobeNewswire) +5.67% -5.43%
Mar-11-24 07:42AM	Lexeo Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Operational Highlights (GlobeNewswire)
07:30AM	Lexeo Therapeutics Announces Oversubscribed $95.0 Million Equity Financing (GlobeNewswire)
Feb-05-24 07:00AM	Lexeo Therapeutics Strengthens Clinical Development Leadership with New Executive Appointments (GlobeNewswire)
Jan-03-24 07:00AM	Lexeo Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-18-23 07:00AM	Lexeo Therapeutics Granted FDA Fast Track Designation and Orphan Drug Designation for LX2020, an AAV-Based Gene Therapy Candidate for PKP2 Arrhythmogenic Cardiomyopathy (ACM) (GlobeNewswire) +8.71%
Dec-13-23 04:59AM	Lexeo Therapeutics Inc (LXEO) Reports Q3 2023 Financial Results and Advances Clinical Programs (GuruFocus.com)
Dec-11-23 12:05PM	LXEO Stock Earnings: Lexeo Therapeutics Reported Results for Q3 2023 (InvestorPlace) -12.94%
07:00AM	Lexeo Therapeutics Reports Third Quarter 2023 Financial Results and Operational Highlights (GlobeNewswire)
Nov-30-23 08:42AM	J.P. Morgan Recommends These 2 Strong Buy Stocks With Over 60% Upside Potential (TipRanks)
Nov-02-23 09:51PM	Lexeo Therapeutics Announces Pricing of Initial Public Offering (GlobeNewswire)

Lexeo Therapeutics, Inc. is a clinical stage genetic medicine company, which engages in the development of therapies for hereditary and acquired diseases. The firm focuses on the medication of genetically defined cardiovascular diseases and sub-group of Alzheimer's disease. It offers LX2006 for the treatment of patients with Friedreich's ataxia, cardiomyopathy, and LX1001 for APOE4 homozygous patients with Alzheimer's disease. The company was founded by Ronald G. Crystal in February 2017 and is headquartered in New York, NY.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Townsend Richard Nolan	Chief Executive Officer	Nov 18 '25	Sale	9.27	1,127	10,447	240,991	Nov 20 05:21 PM
Adler Eric	Chief Medical Officer	Nov 18 '25	Sale	9.27	615	5,701	72,646	Nov 20 05:20 PM
See Tai Sandi	Chief Development Officer	Nov 18 '25	Sale	9.27	386	3,578	65,476	Nov 20 05:19 PM
Robertson Jenny	Chief Legal Officer	Nov 18 '25	Sale	9.27	549	5,089	68,381	Nov 20 05:18 PM
Otero Jose Manuel	Chief Technical Officer	Aug 18 '25	Sale	9.27	721	6,684	63,476	Nov 20 05:14 PM
Robertson Jenny	Officer	Nov 18 '25	Proposed Sale	9.27	549	5,092		Nov 18 03:45 PM
See Tai Sandi	Officer	Nov 18 '25	Proposed Sale	9.27	386	3,580		Nov 18 03:38 PM
Otero Jose Manuel	Officer	Nov 18 '25	Proposed Sale	9.27	721	6,687		Nov 18 03:37 PM
Adler Eric	Officer	Nov 18 '25	Proposed Sale	9.27	615	5,704		Nov 18 03:31 PM
Townsend Richard Nolan	Officer	Nov 18 '25	Proposed Sale	9.27	1,127	10,452		Nov 18 03:12 PM
See Tai Sandi	Chief Development Officer	Oct 17 '25	Sale	8.94	3,888	34,767	65,862	Oct 17 07:29 PM
Robertson Jenny	Chief Legal Officer	Oct 17 '25	Sale	8.94	3,526	31,530	68,930	Oct 17 07:28 PM
Otero Jose Manuel	Chief Technical Officer	Oct 17 '25	Sale	8.94	2,115	18,913	64,197	Oct 17 07:28 PM
Adler Eric	Chief Medical Officer	Oct 17 '25	Sale	8.94	3,382	30,242	73,261	Oct 17 07:26 PM
Townsend Richard Nolan	Chief Executive Officer	Oct 17 '25	Sale	8.94	13,133	117,436	242,118	Oct 17 07:26 PM
Adler Eric	Officer	Oct 17 '25	Proposed Sale	8.94	3,382	30,242		Oct 17 04:30 PM
Otero Jose Manuel	Officer	Oct 17 '25	Proposed Sale	8.94	2,115	18,913		Oct 17 04:15 PM
Robertson Jenny	Officer	Oct 17 '25	Proposed Sale	8.94	3,526	31,530		Oct 17 04:14 PM
Townsend Richard Nolan	Officer	Oct 17 '25	Proposed Sale	8.94	13,133	117,437		Oct 17 04:10 PM
See Tai Sandi	Officer	Oct 17 '25	Proposed Sale	8.94	3,888	34,767		Oct 17 04:08 PM
Otero Jose Manuel	Chief Technical Officer	Aug 18 '25	Sale	4.67	2,848	13,294	60,372	Aug 20 05:05 PM
Robertson Jenny	Chief Legal Officer	Aug 18 '25	Sale	4.67	542	2,530	62,556	Aug 20 05:03 PM
Adler Eric	Chief Medical Officer	Aug 18 '25	Sale	4.67	608	2,838	67,073	Aug 20 05:02 PM
Townsend Richard Nolan	Chief Executive Officer	Aug 18 '25	Sale	4.67	2,735	12,767	220,058	Aug 20 05:00 PM
See Tai Sandi	Chief Development Officer	Aug 18 '25	Sale	4.67	382	1,783	58,860	Aug 20 04:58 PM
Otero Jose Manuel	Officer	Aug 18 '25	Proposed Sale	4.67	2,848	13,295		Aug 18 03:31 PM
Adler Eric	Officer	Aug 18 '25	Proposed Sale	4.67	608	2,838		Aug 18 03:26 PM
Townsend Richard Nolan	Officer	Aug 18 '25	Proposed Sale	4.67	1,115	5,205		Aug 18 03:24 PM
See Tai Sandi	Officer	Aug 18 '25	Proposed Sale	4.67	382	1,783		Aug 18 03:20 PM
Robertson Jenny	Officer	Aug 18 '25	Proposed Sale	4.67	542	2,530		Aug 18 03:18 PM
Townsend Richard Nolan	Chief Executive Officer	May 16 '25	Sale	2.77	1,074	2,979	221,173	May 20 05:00 PM
Adler Eric	Chief Medical Officer	May 16 '25	Sale	2.77	585	1,623	67,681	May 20 05:00 PM
Robertson Jenny	Chief Legal Officer	May 16 '25	Sale	2.77	521	1,445	63,098	May 20 05:00 PM
See Tai Sandi	Chief Development Officer	May 16 '25	Sale	2.77	367	1,018	59,242	May 20 05:00 PM
Townsend Richard Nolan	Officer	May 16 '25	Proposed Sale	2.77	1,074	2,980		May 16 03:51 PM
Robertson Jenny	Officer	May 16 '25	Proposed Sale	2.77	521	1,445		May 16 03:41 PM
See Tai Sandi	Officer	May 16 '25	Proposed Sale	2.77	367	1,018		May 16 03:36 PM
Adler Eric	Officer	May 16 '25	Proposed Sale	2.77	585	1,623		May 16 03:35 PM
Townsend Richard Nolan	Chief Executive Officer	Feb 19 '25	Sale	4.41	4,326	19,091	220,119	Feb 21 05:10 PM
See Tai Sandi	Chief Development Officer	Feb 19 '25	Sale	4.41	1,486	6,558	53,889	Feb 21 05:09 PM
Adler Eric	Chief Medical Officer	Feb 19 '25	Sale	4.41	2,359	10,410	68,266	Feb 21 05:09 PM
Robertson Jenny	Chief Legal Officer	Feb 19 '25	Sale	4.41	2,101	9,272	57,899	Feb 21 05:08 PM
Townsend Richard Nolan	Officer	Feb 19 '25	Proposed Sale	4.41	4,326	19,091		Feb 19 04:25 PM
Robertson Jenny	Officer	Feb 19 '25	Proposed Sale	4.41	2,101	9,272		Feb 19 04:19 PM
See Tai Sandi	Officer	Feb 19 '25	Proposed Sale	4.41	1,486	6,558		Feb 19 04:15 PM
Adler Eric	Officer	Feb 19 '25	Proposed Sale	4.41	2,359	10,410		Feb 19 04:06 PM

Open in Screener

VERA

Vera Therapeutics Inc

Feb 13 • 04:00PM ET

42.22

-0.02 -0.05 %

Healthcare • Biotechnology • USA • NASD

VERA Vera Therapeutics Inc daily Stock Chart

Peers: ARVN INCY ITCI ALXO BCRX RIGL LGND KURA CRVS AVIR

| Held by: VTI XBI IWM VXF IWO IBB VTWO SCHA VHT FESM

Index	RUT	P/E	-	EPS (ttm)	-3.99	Insider Own	19.05%	Shs Outstand	63.89M	Perf Week	-2.94%
Market Cap	2.96B	Forward P/E	-	EPS next Y	-4.66	Insider Trans	-0.32%	Shs Float	56.72M	Perf Month	-12.79%
Enterprise Value	2.54B	PEG	-	EPS next Q	-1.28	Inst Own	84.90%	Short Float	14.27%	Perf Quarter	35.84%
Income	-251.94M	P/S	-	EPS this Y	-64.80%	Inst Trans	-1.77%	Short Ratio	5.97	Perf Half Y	98.50%
Sales	0.00M	P/B	6.76	EPS next Y	-2.92%	ROA	-56.87%	Short Interest	8.09M	Perf YTD	-16.63%
Book/sh	6.24	P/C	5.95	EPS next 5Y	2.47%	ROE	-73.25%	52W High	56.05 -24.67%	Perf Year	23.52%
Cash/sh	7.10	P/FCF	-	EPS past 3/5Y	-21.52% 4.49%	ROIC	-52.97%	52W Low	18.53 127.85%	Perf 3Y	462.93%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	5.03% 5.27%	Perf 5Y	-
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	-53.44%	Oper. Margin	-	ATR (14)	2.36	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	12.09	Sales Y/Y TTM	-	Profit Margin	-	RSI (14)	41.99	Recom	1.29
Dividend Gr. 3/5Y	- -	Current Ratio	12.09	EPS Q/Q	-48.06%	SMA20	-5.45%	Beta	1.17	Target Price	75.15
Payout	-	Debt/Eq	0.19	Sales Q/Q	-	SMA50	-9.99%	Rel Volume	1.18	Prev Close	42.24
Employees	112	LT Debt/Eq	0.19	Earnings	Nov 05 BMO	SMA200	38.91%	Avg Volume	1.36M	Price	42.22
IPO	May 14, 2021	Option/Short	Yes / Yes	EPS/Sales Surpr.	-8.40% -	Trades		Volume	1,603,312	Change	-0.05%

Date	Action	Analyst	Rating Change	Price Target Change
Oct-16-25	Initiated	BofA Securities	Buy	$48
Aug-04-25	Downgrade	Wolfe Research	Outperform → Peer Perform
May-05-25	Resumed	H.C. Wainwright	Buy	$75
Feb-04-25	Initiated	Wolfe Research	Outperform	$49
Jan-28-25	Initiated	Goldman	Buy	$58
Nov-21-24	Initiated	Wells Fargo	Overweight	$70
Oct-16-24	Initiated	Scotiabank	Sector Outperform
Jan-25-24	Initiated	Oppenheimer	Outperform	$26
Jan-08-24	Initiated	Cantor Fitzgerald	Overweight
Dec-18-23	Initiated	Raymond James	Outperform	$29
Nov-10-23	Upgrade	Jefferies	Hold → Buy	$18 → $26
Aug-16-23	Initiated	Guggenheim	Buy	$27
Jan-04-23	Downgrade	Wedbush	Outperform → Neutral	$33 → $8
Jan-04-23	Downgrade	Jefferies	Buy → Hold	$32 → $6
Jul-12-22	Initiated	JP Morgan	Overweight	$35
May-02-22	Initiated	H.C. Wainwright	Buy	$35
Apr-19-22	Initiated	Wedbush	Outperform	$32

Show Previous Ratings

Feb-07-26 11:35AM	Vera Therapeutics, Inc. (VERA): A Bull Case Theory (Insider Monkey)
Feb-06-26 04:05PM	Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +6.23%
Jan-30-26 12:24AM	Is Vera Therapeutics (VERA) One of the Best High Short Interest Stocks with Biggest Upside Potential? (Insider Monkey)
Jan-28-26 07:30AM	Vera Therapeutics Announces Appointment of Matt Skelton to Chief Commercial Officer (GlobeNewswire)
Jan-23-26 11:09AM	Clinical Success Lifts Vera (VERA) Shares, Boosting Fund Returns (Insider Monkey)
11:35AM	Loading…
Jan-15-26 11:35AM	Vera Therapeutics, Inc. (VERA) Granted FDA Priority Review For Atacicept (Insider Monkey)
Jan-14-26 09:55AM	Wall Street Analysts See a 53.05% Upside in Vera Therapeutics (VERA): Can the Stock Really Move This High? (Zacks)
Jan-09-26 01:05PM	Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jan-08-26 07:30AM	Vera Therapeutics to Participate in the 44th Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Jan-07-26 07:41PM	Why Vera Therapeutics Stock Zoomed Higher Today (Motley Fool)
07:30AM	Vera Therapeutics Announces U.S. FDA Granted Priority Review to Biologics License Application for Atacicept for Treatment of Adults with IgA Nephropathy (GlobeNewswire)
Dec-09-25 08:57PM	Vera Therapeutics Announces Pricing of Public Offering of Class A Common Stock (GlobeNewswire)
Dec-08-25 04:01PM	Vera Therapeutics Announces Proposed Public Offering of Class A Common Stock (GlobeNewswire)
Dec-05-25 04:05PM	Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +5.37%
Dec-02-25 07:42PM	Why Vera Therapeutics Stock Rocked the Market on Tuesday (Motley Fool) +12.88% +10.77%
01:09PM	Loading…
01:09PM	Stock Market Today: MongoDB, Boeing, and Intel Define Tuesday Trade As Market Bounces Back From Post-Thanksgiving Blues (TheStreet)
Nov-26-25 07:45PM	Why Vera Therapeutics Stock Crushed it Today (Motley Fool) +13.25%
04:05PM	Vera Therapeutics Appoints Veteran Biotech Executive James R. Meyers to its Board of Directors (GlobeNewswire)
Nov-24-25 07:25AM	Vera Therapeutics to Participate at Upcoming Investor Conferences (GlobeNewswire)
Nov-18-25 02:20PM	Vera Therapeutics Stock Earns RS Rating Upgrade (Investor's Business Daily)
Nov-16-25 10:14PM	H.C. Wainwright Maintains Its Bullish Stance on Vera Therapeutics (VERA), Sees Strong Future Revenue Growth (Insider Monkey)
Nov-14-25 09:01AM	Yale University's Strategic Investment in Vera Therapeutics Inc: A 32.26% Portfolio Stake (GuruFocus.com)
Nov-10-25 07:29AM	Vera Therapeutics to Participate in the TD Cowen Immunology & Inflammation Summit (GlobeNewswire) +14.72%
Nov-07-25 06:27PM	Vera Therapeutics Submits Biologics License Application to U.S. FDA through Accelerated Approval Program for Atacicept for the Treatment of Adults with IgA Nephropathy (GlobeNewswire)
04:05PM	Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Nov-06-25 09:51AM	Vera Therapeutics Announces Positive ORIGIN Phase 3 Data for Atacicept in IgA Nephropathy Presented at ASN Kidney Week 2025 and Published in the New England Journal of Medicine (GlobeNewswire)
Nov-05-25 07:29AM	Vera Therapeutics Provides Business Update and Reports Third Quarter 2025 Financial Results (GlobeNewswire)
Oct-22-25 08:00AM	Vera Therapeutics to Host an Investor Call and Webcast to Provide an ORIGIN 3 Update on November 6, 2025 at 4:30 pm ET (GlobeNewswire)
Oct-20-25 11:08PM	BofA Initiates Coverage of Vera Therapeutics (VERA) With a Buy Rating (Insider Monkey)
Oct-17-25 09:12AM	Vera Therapeutics Announces ORIGIN 3 Late-Breaking Abstract Selected as Featured Oral Presentation at Opening Plenary Session of ASN Kidney Week 2025 (GlobeNewswire)
04:05PM	Loading…
Oct-10-25 04:05PM	Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Sep-05-25 04:05PM	Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +10.46%
Aug-26-25 04:05PM	Vera Therapeutics to Participate at Upcoming Investor Conferences (GlobeNewswire) +5.62%
Aug-08-25 04:05PM	Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Aug-05-25 07:00AM	Vera Therapeutics Provides Business Update and Reports Second Quarter 2025 Financial Results (GlobeNewswire)
Aug-04-25 09:35AM	Coinbase downgraded, Spotify upgraded: Wall Street's top analyst calls (The Fly)
Jul-10-25 07:05PM	Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jul-02-25 08:07AM	Millions in Insider Buying Point to These 2 Stocks Heres What It Could Signal (TipRanks)
Jun-12-25 01:57PM	Analysts Can't Get Enough of These Little-Known Biopharma Stocks (MarketBeat)
Jun-09-25 04:05PM	Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jun-06-25 11:02AM	Biotech Stock Vera Is Slumping After Monster Gain (Barrons.com) -25.89%
07:49AM	Vera Therapeutics stock sinks following competitors successful trial (Investing.com)
Jun-04-25 04:05PM	Vera Therapeutics to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference (GlobeNewswire)
Jun-03-25 06:30AM	Vera Therapeutics Announces Refinancing of Existing Oxford Debt Facility, Providing up to $500 Million of Term Loans (GlobeNewswire)
02:22AM	Why Vera Therapeutics, Inc. (VERA) Skyrocketed On Monday (Insider Monkey)
Jun-02-25 06:30AM	Vera Therapeutics Announces Atacicept Achieved 46% Proteinuria Reduction in ORIGIN Phase 3 Trial in Adults with IgA Nephropathy (GlobeNewswire) +67.49%
04:51AM	Vera drug scores in closely watched study in rare kidney disease (BioPharma Dive)
May-09-25 04:05PM	Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
May-06-25 08:00AM	Vera Therapeutics Provides Business Update and Reports First Quarter 2025 Financial Results (GlobeNewswire) -13.79%
Apr-09-25 04:05PM	Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +16.76%
02:51PM	Kidney Disease-Focused Vera Therapeutics Concludes Enrollment In Pivotal Study, Targets 2026 Commercial Launch (Benzinga)
Apr-03-25 08:00AM	Vera Therapeutics Completes Full Enrollment in Pivotal ORIGIN Phase 3 Trial for Atacicept in IgAN (GlobeNewswire)
Mar-11-25 04:28PM	Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Feb-27-25 08:00AM	Vera Therapeutics to Participate in the TD Cowen 45th Annual Health Care Conference (GlobeNewswire) +5.91%
Feb-26-25 08:25AM	Vera Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2024 Financial Results (GlobeNewswire)
Feb-13-25 04:05PM	Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -19.66%
Jan-14-25 04:05PM	Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jan-13-25 07:00AM	Vera Therapeutics Acquires Global Rights to Novel, Next Generation Dual BAFF/APRIL Inhibitor (GlobeNewswire) -6.08%
Jan-07-25 04:05PM	Vera Therapeutics to Participate in the 43rd Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-09-24 06:29PM	Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Nov-22-24 04:05PM	Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Nov-18-24 08:00AM	Vera Therapeutics Appoints Jason S. Carter as Chief Legal Officer (GlobeNewswire)
Nov-11-24 04:05PM	Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
09:55AM	Wall Street Analysts Think Vera Therapeutics (VERA) Could Surge 27.26%: Read This Before Placing a Bet (Zacks)
08:00AM	Vera Therapeutics Partners with University of Michigan on the NEPTUNE Match Project and PIONEER Study (GlobeNewswire)
Nov-08-24 04:05PM	Vera Therapeutics to Participate at Upcoming Investor Conferences (GlobeNewswire)
Nov-07-24 08:00AM	Vera Therapeutics Provides Business Update and Reports Third Quarter 2024 Financial Results (GlobeNewswire)
Oct-29-24 08:21PM	Vera Therapeutics Announces Pricing of Public Offering of Class A Common Stock (GlobeNewswire) -9.23% -5.42%
09:25AM	Vera Therapeutics price target raised to $64 from $56 at Guggenheim (TipRanks)
Oct-28-24 05:43PM	Vera Therapeutics Breaks Out On Promising Results For Kidney Drug (Investor's Business Daily) +15.21%
05:37PM	Vera Therapeutics Announces Proposed Public Offering of Class A Common Stock (GlobeNewswire)
10:33AM	Vera Therapeutics' Atacicept Shows Sustained, Substantial Improvement In Kidney Function For Patients At Almost Two Years (Benzinga)
10:13AM	Vera Therapeutics Eyes Breakout On Promising Results For Kidney Drug (Investor's Business Daily)
Oct-26-24 07:30PM	Vera Therapeutics Announces 96-week eGFR Stabilization in ORIGIN Phase 2b Study of Atacicept in IgAN in a Late-Breaking Oral Presentation at the American Society of Nephrology Kidney Week 2024 (GlobeNewswire)
Oct-04-24 04:05PM	Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Oct-02-24 06:30AM	Vera Therapeutics Announces Late-Breaking Oral Presentation of ORIGIN Phase 2b Long-term Results at the American Society of Nephrology Kidney Week 2024 (GlobeNewswire)
06:30AM	Vera Therapeutics Announces Expanded Atacicept Development Program In Multiple Autoimmune Kidney Diseases (GlobeNewswire)
Sep-26-24 03:31PM	Is Vera Therapeutics Inc. (VERA) the Best Performing Small-Cap Stock in 2024? (Insider Monkey)
Sep-16-24 08:00AM	Vera Therapeutics to Host In-Person R&D Day in New York to Discuss Potential Indication Expansion for Atacicept on October 2, 2024 (GlobeNewswire) +6.90%
Sep-12-24 08:00AM	Vera Therapeutics Completes Enrollment for Primary Endpoint in Pivotal Phase 3 ORIGIN 3 Trial of Atacicept in IgAN (GlobeNewswire) -5.08%
Sep-10-24 04:05PM	Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Sep-05-24 01:07AM	Vera Therapeutics, Inc. (VERA): Among the Best Mid-Cap Healthcare Stocks To Buy Now (Insider Monkey)
Sep-03-24 08:27AM	Adobe Stock Added to JP Morgan Focus List. Heres Why. (Barrons.com)
08:27AM	Adobe and 2 More Stocks Added to JP Morgan Focus List. Heres Why. (Barrons.com)
07:49AM	Load Up on Adobe and These 2 Stocks This September, J.P. Morgan Says (Barrons.com)
Sep-02-24 06:05PM	10 Best Mid-Cap Healthcare Stocks To Buy Now (Insider Monkey)
Aug-29-24 08:00AM	Vera Therapeutics to Participate at September Investor Conferences (GlobeNewswire)
Aug-09-24 04:05PM	Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Aug-08-24 08:00AM	Vera Therapeutics Provides Business Update and Reports Second Quarter 2024 Financial Results (GlobeNewswire)
Jul-05-24 04:30PM	Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jul-01-24 08:00AM	Vera Therapeutics Announces Appointment of Industry Veteran David L. Johnson as Chief Operating Officer (GlobeNewswire)
Jun-11-24 04:01PM	Vera Therapeutics Appoints Christy J. Oliger to Board of Directors (GlobeNewswire)
Jun-07-24 04:05PM	Vera Therapeutics to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference (GlobeNewswire)
04:05PM	Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
May-28-24 08:00AM	Vera Therapeutics Receives U.S. FDA Breakthrough Therapy Designation for Atacicept in Immunoglobulin A Nephropathy (IgAN) (GlobeNewswire)
May-25-24 09:40AM	Vera Therapeutics Presents 72-week eGFR Stabilization and Rapid Hematuria Improvement in Phase 2b ORIGIN Study of Atacicept in IgAN at the 61st European Renal Association Congress (GlobeNewswire)
May-17-24 04:27PM	Vera Therapeutics Insider Sold Shares Worth $1,304,435, According to a Recent SEC Filing (MT Newswires)
May-10-24 05:38AM	Wedbush Adjusts Vera Therapeutics' PT to $32 From $34, Keeps Neutral Rating (MT Newswires)
May-09-24 01:53PM	VERA Stock Earnings: Vera Therapeutics Misses EPS for Q1 2024 (InvestorPlace) -5.81%
08:00AM	Vera Therapeutics Provides Business Update and Reports First Quarter 2024 Financial Results (GlobeNewswire)

Vera Therapeutics, Inc. is a clinical stage biotechnical company which engages in the development and commercialization of transformative treatments for immunological diseases. The company was founded by Marshall Fordyce in May 2016 and is headquartered in Brisbane, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Turner William D.	Chief Regulatory Officer	Dec 15 '25	Option Exercise	15.53	10,000	155,300	32,500	Dec 17 04:05 PM
Turner William D.	Chief Regulatory Officer	Dec 15 '25	Sale	50.08	10,000	500,767	22,500	Dec 17 04:05 PM
ENRIGHT PATRICK G	Director	Dec 11 '25	Buy	42.50	5,882	249,985	5,882	Dec 15 08:07 PM
WILLIAM TURNER	Officer	Dec 15 '25	Proposed Sale	49.80	10,000	498,000		Dec 15 04:17 PM
Turner William D.	Chief Regulatory Officer	Dec 08 '25	Option Exercise	15.53	10,000	155,300	32,500	Dec 10 04:05 PM
Turner William D.	Chief Regulatory Officer	Dec 08 '25	Sale	45.31	10,000	453,053	22,500	Dec 10 04:05 PM
WILLIAM TURNER	Officer	Dec 08 '25	Proposed Sale	44.90	10,000	449,000		Dec 08 04:41 PM
Turner William D.	Chief Regulatory Officer	Dec 03 '25	Option Exercise	15.53	10,000	155,300	32,500	Dec 04 04:05 PM
Turner William D.	Chief Regulatory Officer	Dec 03 '25	Sale	40.00	10,000	400,000	22,500	Dec 04 04:05 PM
WILLIAM TURNER	Officer	Dec 03 '25	Proposed Sale	37.25	10,000	372,500		Dec 03 04:31 PM
Carter Jason S	Chief Legal Officer	Nov 21 '25	Sale	27.82	3,864	107,498	49,136	Nov 25 04:05 PM
Carter Jason S	Officer	Nov 21 '25	Proposed Sale	27.87	3,864	107,690		Nov 24 09:22 PM
Young Joseph R	SVP, FINANCE, CHIEF ACCT OFFCR	Nov 13 '25	Option Exercise	3.94	10,000	39,396	57,839	Nov 13 08:57 PM
Young Joseph R	SVP, FINANCE, CHIEF ACCT OFFCR	Nov 11 '25	Sale	29.06	15,000	435,874	47,839	Nov 13 08:57 PM
ENRIGHT PATRICK G	Director	Jun 23 '25	Buy	20.87	209,393	4,369,676	3,569,522	Jun 25 08:07 PM
ENRIGHT PATRICK G	Director	Jun 24 '25	Buy	22.35	40,607	907,635	3,596,593	Jun 25 08:07 PM
Fordyce Marshall	PRESIDENT AND CEO	Feb 21 '25	Sale	27.89	10,613	296,032	213,740	Feb 27 04:05 PM
Fordyce Marshall	PRESIDENT AND CEO	Feb 26 '25	Sale	27.65	9,075	250,882	204,665	Feb 27 04:05 PM
MARSHALL FORDYCE	Director	Feb 26 '25	Proposed Sale	27.10	9,075	245,932		Feb 26 04:21 PM

LXEO

Lexeo Therapeutics Inc

VERA

Vera Therapeutics Inc

Upgrade your FINVIZ experience